ASCO 2019: The first gene expression analysis of patients with advanced breast cancer treated with ribociclib-containing therapy

Yen-Shen Lu | | Juni 6, 2019

Föreläsare: Yen-Shen Lu

The Phase III MONALEESA-7 study demonstrated that the addition of ribociclib to a nonsteroidal aromatase inhibitor or tamoxifen + goserelin significantly extended progression-free survival. In this MEDtalk Yen-Shen Lu explain the effect across gene expression subgroups